FDA grants orphan-drug designation for TauRx’s LMTX in frontotemporal dementia

FDA grants orphan-drug designation for TauRx’s LMTX in frontotemporal dementia

ABERDEEN, Scotland and Singapore, 10th December, 2018 – TauRx, a leader in neurodegenerative disease research, today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to LMTX® for the
"treatment of frontotemporal dementia". The term Frontotemporal Dementia (FTD) covers a number of sub-types of dementia, all of which are characterized by a progressive loss of neurons in the frontal and/or temporal lobes of the brain.

Read more here.